.png)
 b.png)
Engineered radiopharmaceuticals that deliver lethal radiation with surgical accuracy — destroying cancer cells while preserving healthy tissue.
Powerful enough to kill tumors. Too dangerous for healthy cells. Until now.
Our proprietary platform combines advanced ligand design, optimized chelators, and therapeutic isotopes to create targeted radiopharmaceuticals that deliver lethal radiation only to cancer cells.
One dose. One target. Maximum impact.
Every component engineered for unmatched specificity, stability, and therapeutic power — from ligand to isotope.
Bind exclusively to tumor-specific receptors with sub-nanomolar affinity for zero off-target effects.
Lock radioisotopes with extreme stability — no leakage, no damage to healthy organs.
High-LET alpha particles for DNA destruction; beta for deeper tissue penetration.
Rapid clearance from healthy organs, prolonged retention in tumors for maximum efficacy.
Precision isn't theoretical — it's measurable in lives saved and quality preserved.
Tumor Targeting Accuracy
Reduction in Side Effects
Single-Dose Protocol
Pediatric Applications
From discovery to clinic — advancing multiple candidates across solid tumors and rare cancers.
mCRPC (Prostate Cancer); PSMA+ Solid Tumors
Pre-IND Underway
Pancreatic and FAP-high Solid Tumors
Optimization
Broad Solid Tumors (EPR-driven uptake)
Discovery / Platform Build
Patient Selection and Response Tracking (PSMA PET Diagnostic)
Preclinical
Patient Selection for FAP-targeted Therapy (FAP PET Diagnostic)
Preclinical
Join us in redefining what's possible in oncology. Precision. Power. Hope.
Partner With UsA next-generation prodrug strategy engineered to unlock anti-inflammatory potency while eliminating systemic toxicity.
The prodrug remains inert in circulation and is selectively activated at disease-relevant tissue microenvironments, ensuring localized efficacy.
By avoiding widespread PDE4 inhibition, gastrointestinal and CNS-related side effects are significantly minimized.
Designed for once-daily oral dosing with consistent exposure and predictable pharmacokinetics.
Every component of Ayutara’s platform is engineered to deliver radiation with surgical accuracy — sparing healthy tissue while maximizing tumor kill.
Precision delivery results in higher tumor residence time, lower toxicity, and reproducible clinical performance across patient populations.